These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 1818823)

  • 21. Endotoxin in storage medium of human corneal grafts and clinical course after penetrating normal-risk keratoplasty.
    Spelsberg H; Reinhard T; Sokolovska Y; Zysk G; Böhringer D; Sundmacher R
    Eye (Lond); 2004 Sep; 18(9):923-8. PubMed ID: 15002025
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Corneal transplant rejection rate and severity after endothelial keratoplasty.
    Allan BD; Terry MA; Price FW; Price MO; Griffin NB; Claesson M
    Cornea; 2007 Oct; 26(9):1039-42. PubMed ID: 17893530
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Advantages and limits of multiple grafts (third keratoplasty) under local cyclosporin 2%].
    Alalwani H; Omer Saleh B; Rocher N; Renard G; Bourges JL; Legeais JM
    J Fr Ophtalmol; 2010 Dec; 33(10):710-4. PubMed ID: 21093105
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Systemic cyclosporin A therapy in high risk keratoplasty].
    Bialasiewicz AA; Naumann GO
    Fortschr Ophthalmol; 1989; 86(6):574-80. PubMed ID: 2625283
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful penetrating keratoplasty in a patient with severe atopic keratoconjunctivitis and elevated serum IgE level treated with long-term topical cyclosporin A.
    Geggel HS
    Cornea; 1994 Nov; 13(6):543-5. PubMed ID: 7842716
    [No Abstract]   [Full Text] [Related]  

  • 26. Long-term effects of topical cyclosporine A treatment after penetrating keratoplasty.
    Inoue K; Amano S; Kimura C; Sato T; Fujita N; Kagaya F; Kaji Y; Oshika T; Tsuru T; Araie M
    Jpn J Ophthalmol; 2000; 44(3):302-5. PubMed ID: 10913651
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Immunological aspects of corneal graft rejection and own experience in immunosuppressive therapy in high risk patients].
    Kamińska A; Szaflik J; Minkiewicz-Timler G; Sybilska M; Pawluczyk-Dyjecińska M; Smolarek M
    Klin Oczna; 2004; 106(3 Suppl):485-8. PubMed ID: 15636244
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Initial endothelial cell density and chronic endothelial cell loss rate in corneal transplants with late endothelial failure.
    Nishimura JK; Hodge DO; Bourne WM
    Ophthalmology; 1999 Oct; 106(10):1962-5. PubMed ID: 10519593
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of topical cyclosporine A 2% in prevention of graft rejection in high-risk keratoplasty: a randomized controlled trial.
    Sinha R; Jhanji V; Verma K; Sharma N; Biswas NR; Vajpayee RB
    Graefes Arch Clin Exp Ophthalmol; 2010 Aug; 248(8):1167-72. PubMed ID: 20414783
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Risk factors for the first episode of corneal graft rejection in keratoconus.
    Epstein AJ; de Castro TN; Laibson PR; Cohen EJ; Rapuano CJ
    Cornea; 2006 Oct; 25(9):1005-11. PubMed ID: 17133044
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Subconjunctival interleukin-1 receptor antagonist inhibits graft rejection following high-risk penetrating keratoplasty in rats].
    Zhou J; Lu XH; Dang ST; Bai L; Zhang YQ; Xu N
    Di Yi Jun Yi Da Xue Xue Bao; 2004 May; 24(5):539-41. PubMed ID: 15151827
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk factors for corneal allograft rejection: intermediate results of a prospective normal-risk keratoplasty study.
    Küchle M; Cursiefen C; Nguyen NX; Langenbucher A; Seitz B; Wenkel H; Martus P; Naumann GO
    Graefes Arch Clin Exp Ophthalmol; 2002 Jul; 240(7):580-4. PubMed ID: 12136292
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Chronic endothelial cell loss of the graft after penetrating keratoplasty: influence of endothelial cell migration from graft to host].
    Reinhard T; Böhringer D; Hüschen D; Sundmacher R
    Klin Monbl Augenheilkd; 2002 Jun; 219(6):410-6. PubMed ID: 12136435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Use of topical cyclosporin in microcrystalline keratopathy due to Streptococcus].
    Touzeau O; Borderie V; Razavi S; Warnet JM; Laroche L
    J Fr Ophtalmol; 1999; 22(6):662-5. PubMed ID: 10434201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Clinical aspects and treatment of immune reactions following penetrating normal-risk keratoplasty].
    Nguyen NX; Seitz B; Langenbucher A; Wenkel H; Cursiefen C
    Klin Monbl Augenheilkd; 2004 Jun; 221(6):467-72. PubMed ID: 15236106
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cytomegalovirus keratitis after penetrating keratoplasty.
    Wehrly SR; Manning FJ; Proia AD; Burchette JL; Foulks GN
    Cornea; 1995 Nov; 14(6):628-33. PubMed ID: 8575188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Penetrating keratoplasty in Asian eyes: the Singapore Corneal Transplant Study.
    Tan DT; Janardhanan P; Zhou H; Chan YH; Htoon HM; Ang LP; Lim LS
    Ophthalmology; 2008 Jun; 115(6):975-982.e1. PubMed ID: 18061267
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclosporin A in perforating keratoplasty.
    Sundmacher R; Reinhard T
    Cesk Slov Oftalmol; 1995 Oct; 51(5):271-6. PubMed ID: 8948156
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Corneal transplant survival after onset of severe endothelial rejection.
    Wagoner MD; Ba-Abbad R; Sutphin JE; Zimmerman MB
    Ophthalmology; 2007 Sep; 114(9):1630-6. PubMed ID: 17367863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic cyclosporine in high-risk keratoplasty. Short- versus long-term therapy.
    Hill JC
    Ophthalmology; 1994 Jan; 101(1):128-33. PubMed ID: 8302545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.